Reduced-intensity transplantation for lymphoma.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Non-myeloablative stem cell transplantation, now termed reduced-intensity transplantation (RIT), was developed to avoid intensive preparative regimens.
• RIT aims to achieve disease eradication through graft-versus-malignancy effects by allowing donor and host hematopoietic coexistence (chimerism).

Purpose of the Study:

• To review the current understanding and application of reduced-intensity transplantation (RIT) in clinical practice.
• To discuss the efficacy, challenges, and future directions of RIT, particularly for non-Hodgkin's lymphomas.

Main Methods:

• Review of established RIT regimens, often incorporating purine analogs (e.g., fludarabine) and alkylating agents (e.g., cyclophosphamide, melphalan), with or without low-dose total body irradiation.
• Evaluation of the role of T-cell-depleting monoclonal antibodies (e.g., alemtuzumab) in mitigating graft-versus-host disease.
• Discussion of the graft-versus-lymphoma (GVL) phenomenon and its contribution to outcomes in RIT.

Main Results:

• RIT regimens allow for donor-host chimerism, leveraging graft-versus-malignancy effects.
• The addition of alemtuzumab may reduce acute graft-versus-host disease.
• The precise contribution of graft-versus-lymphoma to RIT outcomes is still under investigation, with varying susceptibility among lymphoma subtypes.

Conclusions:

• Reduced-intensity transplantation is a valuable alternative to myeloablative regimens but does not eliminate risks.
• Graft-versus-host disease and infections remain significant obstacles, necessitating careful supportive care and graft procurement.
• Future research should focus on minimizing RIT-related risks and identifying patient- and disease-specific predictors of successful outcomes.